Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0ITFBX
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
CD33-11A1-v1417- H16-K222R-hGl-LP17
|
|||||
| Synonyms |
CD33-11A1-v1417- H16-K222R-hGl-LP17
Click to Show/Hide
|
|||||
| Organization |
PFIZER INC.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
1.96
|
|||||
| Structure |
|
|||||
| Antibody Name |
CD33-11A1-v1417- H16-K222R-hGl
|
Antibody Info | ||||
| Antigen Name |
Vesicle-associated membrane protein 8 (VAMP8)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Therapeutic Target |
Stimulator of interferon genes protein (STING1)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
LP17
|
|||||
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 0.71 ng/ml | Positive CD33 expression (CD33+++/++) | ||
| Method Description |
96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
|
||||
| In Vitro Model | Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation | HL60 cells | CVCL_0002 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 12.36 ng/ml | Positive CD33 expression (CD33+++/++) | ||
| Method Description |
96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
|
||||
| In Vitro Model | Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA | NB4 cells | CVCL_0005 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 530 ng/ml | Positive CD33 expression (CD33+++/++) | ||
| Method Description |
96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
|
||||
| In Vitro Model | Esophageal squamous cell carcinoma | TF-1 cells | CVCL_1759 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 2090 ng/ml | Negative CD33 expression (CD33-) | ||
| Method Description |
96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
|
||||
| In Vitro Model | EBV-related Burkitt lymphoma | Raji cells | CVCL_0511 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | > 10000 ng/ml | Positive CD33 expression (CD33+++/++) | ||
| Method Description |
96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
|
||||
| In Vitro Model | Acute erythroid leukemia, Erythroleukemia | HEL92.1.7 cells | CVCL_2481 | ||